MicroRNAs in urine as diagnostic biomarkers for multiple myeloma.

Szczegóły
Abstrakt

Tytuł:: MicroRNAs in urine as diagnostic biomarkers for multiple myeloma.
Autorzy:: Li J; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Wang C; Medical Laboratory Center, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Meng Q; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Hu Z; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Hu M; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Zhang M; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.; Clinical Laboratory Medicine, Peking University Ninth School of Clinical Medicine, Beijing, China.
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2021 Apr; Vol. 43 (2), pp. 227-234. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Oxford : Blackwell Scientific Publications, c2007-
MeSH Terms:: Biomarkers, Tumor*
Cell-Free Nucleic Acids*
MicroRNAs*/urine
Multiple Myeloma/*diagnosis
Multiple Myeloma/*genetics
Adult ; Aged ; Aged, 80 and over ; Computational Biology/methods ; Female ; Gene Expression Profiling/methods ; Gene Expression Regulation ; Humans ; Kaplan-Meier Estimate ; Liquid Biopsy/methods ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/urine ; Prognosis ; RNA Interference ; ROC Curve ; Real-Time Polymerase Chain Reaction ; Transcriptome ; Urinalysis/methods
References:: Stankova M, Kubaczkova V, Sedlarikova L, et al. Circulating microRNA as Biomarkers in Hematological Malignancies. EXS. 2015;106:123-138.
Navarro A, Diaz T, Tovar N, et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget. 2015;6(3):1874-1883.
Rocci A, Hofmeister CC, Geyer S, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014;28(9):922-1926.
Zhao JJ, Lin J, Zhu D, et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res. 2014;74(6):1801-1813.
Li L, Bingxian B, Liang Z, et al. Establishment of urinary micro-RNA detection method and its application in diagnosis of bladder cancer. J Diagn Concepts Pract. 2017;16(1):93-97.
Wanfen Z, Changming Z, Chunbei L, et al. Urinary microRNAs are the biomarker for the disease activity of petients with focal segmental glomerulosclerosis. J Nephrol Dialy Transplant. 2013;22(4):315-323.
Yuzi T, Jinjian S, Fan W, et al. Urine miRNA-200c-3p as potential diagnostic biomarkers for ovarian tumor. Prog Obstet Gynecol. 2016;9(25):658-660.
Sedlaříková L, Bešše L, Novosadová S, et al. MicroRNAs in urine are not biomarkers of multiple myeloma. J Negat Results BioMed. 2015;14:16.
Anderson KC, Alsina M, Atanackovic D, et al. Multiple Myeloma, Version 2.2016. J Natl Compr Cancer Net. 2015;13(11):1398-1435.
Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587-600.
Li J, Zhang M, Wang C. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined ignificance. J Clin Lab Anal. 2020;00:e23233.
Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematol Am Soc Hematol Educ Program. 2017;1:498-507.
Wu P, Agnelli L, Walker BA, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013;162(3):348-359.
Gao X, Zhang R, Xiaoyan Q, et al. MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res. 2012;36(12):1505-1509.
Guo J, Zhao Y, Fei C, et al. Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells. Cell Death Dis. 2018;9(5):512.
Fišerová B, Kubiczková L, Sedlaříková L, et al. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):184-191.
Schena FP, Serino G, Sallustio F. MicroRNAs in kidney diseases: New promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant. 2014;29(4):755-763.
Yan-Ni X, Xiao C-R, Huang Y-D, et al. Circulating Serum MicroRNA as Diagnostic Biomarkers for Multiple Myeloma. J Exp Hematol. 2017;25(2):471-475.
Pan JY, Zhang F, Sun CC, et al. miR-134: A Human Cancer Suppressor? Mol Ther Nucleic Acids. 2017;6(1):140-149.
Solé C, Tramonti D, Schramm M, et al. The Circulating Transcriptome as a Source of Biomarkers for Melanoma. Cancers (Basel). 2019;11(1):E70.
Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511-518.
Du J, Liu S, He J, et al. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget. 2015;6(17):14993-15007.
Mo J-S, Park HW, Guan K-L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642-656.
Jasinski-Bergner S, Reches A, Stoehr C, et al. Identification of Novel microRNAs Regulating HLA-G Expression and Investigating Their Clinical Relevance in Renal Cell Carcinoma. Oncotarget. 2016;17(8):26866-26878.
Zhuo X, Zhou W, Li D, et al. Plasma microRNA Expression Signature Involving miR-548q, miR-630 and miR-940 as Biomarkers for Nasopharyngeal Carcinoma Detection. Cancer Biomark. 2018;23(4):579-587.
Tripathi R, Aier I, Chakraborty P, et al. Unravelling the Role of Long Non-Coding RNA-LINC01087 in Breast Cancer. Noncoding RNA Res. 2019;5(1):1-10.
Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Rev Mol Diagn. 2014;14(1):55-66.
Zhang Li, Pan L, Xiang B, et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget. 2016;7(21):30876-30891.
He H, Weijun F, Jiang H, et al. The clinical characteristics and prognosis of IGH deletion in multiple myeloma. Leuk Res. 2015;39(5):515-519.
Grant Information:: 2019-JS02 Enhancement Funding of Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics
Contributed Indexing:: Keywords: biomarker; microRNA; molecular diagnosis; multiple myeloma
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Cell-Free Nucleic Acids)
0 (MicroRNAs)
Entry Date(s):: Date Created: 20201017 Date Completed: 20210607 Latest Revision: 20210607
Update Code:: 20240105
DOI:: 10.1111/ijlh.13367
PMID:: 33068078
: Czasopismo naukowe

Pełny tekst

Introduction: Multiple myeloma (MM) is a hematological malignancy. It is of great clinical significance to screen microRNAs (miRNAs) in urine as noninvasive diagnostic biomarkers for MM.
Methods: Urinary miRNAs in MM were performed by Agilent Bioanalyzer 2100 and verified by quantitative real-time PCR (qRT-PCR). Receiver operator characteristic (ROC) was used to evaluate the diagnostic value of abnormal miRNAs for MM. Progression-free survival (PFS) of MM was calculated by Kaplan-Meier.
Results: In microarray analysis, twelve down-regulated miRNAs dysregulated in MM. The expression levels of miR-134-5p, miR-6500-5p, miR-548q, and miR-548y were validated. These miRNAs were significantly lower in MM (P < .05), but there was no significant difference between newly diagnosed, relapse, and remission group of MM (P> .05). ROC curve analysis showed that the sensitivity of miR-134-5p, miR-6500-5p, miR-548q, and miR-548y to MM was 91.7%, 100%, 100%, and 91.7%, and the specificity was 66.7%, 75.0%, 75.0%, and 100%, respectively. The four miRNAs were negatively correlated with the total urinary light chain (r = -0.427 P = .030, r = -0.461 P = .018, r = -0.469 P = .016, r = -0.493 P = .011). In addition, miR-134-5p, miR-6500-5p, and miR-548q were positively correlated with serum ALB (r = 0.518 P = .006, r = 0.400 P = .039,r = 0.492 P = .009). The expression level of miRNAs had no significant influence on PFS in MM patients (P> .05).
Conclusion: The results show that miR-134-5p, miR-6500-5p, miR-548q, and miR-548y are potential noninvasive diagnostic biomarkers for MM.
(© 2020 John Wiley & Sons Ltd.)

Informacja